The DEEP project has received research funding from the European Union under the 7th Framework Programme

+39 080 97 51 974

[email protected]

Aims

The DEEP Project has the following major goals:

1. to evaluate pharmacokinetics and pharmacodynamics properties of deferiprone in children less than 6 years of age

2. to evaluate efficacy and safety of deferiprone compared to deferasirox therapy in 1 month to less than 18 year-old children affected by hereditary hemoglobinopathies

3. to provide long-term safety data by analysing all events potentially related to deferiprone use (alone or in combination with deferoxamine) in children aged less than 18 years

Share